top of page

Gilead's Dan O'Day on 1Q23 Earnings

  • blonca9
  • Apr 26, 2023
  • 1 min read

Updated: Jun 16, 2023

BiotechTV's exclusive interview with Gilead Sciences' Chairman & CEO Dan O'Day on the company's Q1 2023 earnings day.



Brad Loncar visited Gilead Science's headquarters in Foster City, California and had the opportunity to interview Chairman and CEO Dan O'Day about Gilead’s business.


Discussed:


- Gilead’s transformation into oncology and other areas.

- The business model of cell therapy.

- The competitive landscape for the ADC medicine Trodelvy.

- Other oncology targets like CD47 and TIGIT.

- Long-acting medicines for HIV.

- What it was like to develop remdesivir during the pandemic.

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

​

​Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page